Results 161 to 170 of about 141,601 (258)

The Future of Telehealth in Allergy and Immunology Training. [PDF]

J Allergy Clin Immunol Pract, 2020
Keswani A, Brooks JP, Khoury P.
europepmc   +1 more source

Advanced Corneal Hydrogels: From Passive Replacement to Active Regeneration and Intelligent Interaction

Advanced Science, EarlyView.
This review charts the evolution of corneal hydrogels from passive replacements to active and intelligent systems, evaluating natural and synthetic materials while addressing design challenges such as transparency and strength. Advanced applications such as scarless wound healing, three‐dimensional bioprinting, and smart wearables are highlighted to ...
Xinwei Wang, Wen Zhou, Haotian Xue, Wenjun Xue, Guangping Gao, Bing Zhu, Hongyuan Song, Qingqiang Xu, Jing Zhao, Wei Shen   +9 more
wiley   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

American Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard, Sarah Bertoli, Rebeca Rodríguez‐Veiga, Celestine Simand, Laura Torres, Pierre Peterlin, Mar Tormo, Rudy Birsen, Juan Miguel Bergua‐Burgues, Emmanuelle Tavernier, Teresa Bernal del Castillo, Martin Carré, Cristina Gil, Adrien Contejean, Eduardo Rodríguez‐Arbolí, Corentin Orvain, Carlos Rodríguez‐Medina, Lauren Veronese, Maria Jose Sayas Lloris, Eric Delabesse, Josefina Serrano, Ariane Mineur, María García‐Fortes, Romain Guieze, Maria Luz Amigo, Arnaud Pigneux, Lorenzo Algarra Algarra, Christian Recher, Pierre‐Yves Dumas, David Martínez‐Cuadrón   +31 more
wiley   +1 more source

Allergy and immunology in young children of Japan: The JECS cohort. [PDF]

World Allergy Organ J, 2020
Yamamoto-Hanada K, Pak K, Saito-Abe M, Yang L, Sato M, Irahara M, Mezawa H, Sasaki H, Nishizato M, Ishitsuka K, Ohya Y, Japan Environment and Children's Study (JECS) Group.   +11 more
europepmc   +1 more source

Legends of allergy and immunology: Donald Y. M. Leung. [PDF]

Allergy, 2020
Szefler SJ.
europepmc   +1 more source

Genetic Contribution to Asthma Informs Acute Chest Syndrome Pathophysiology and Risk Stratification

American Journal of Hematology, EarlyView.
ABSTRACT Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) occurring in ~50% of patients, some presenting frequent episodes. We lack tools to identify patients at high risk of ACS occurrence or frequent episodes. Epidemiological studies have found an association between asthma and ACS, but whether this link is causal is ...
Sara El Aouhel, Vanessa Bellegarde, Stennio Da Silva Faria, Tristan St‐Laurent, Estelle Lecluze, Anne‐Laure Pham Hung d’Alexandry d’Orengiani, Frédéric Galactéros, Pablo Bartolucci, Marc‐André Legault, Guillaume Lettre, Thomas Pincez   +10 more
wiley   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Melissa A. Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R. Mohan, Gregory D. Ayers, Michael T. Byrne, Michael R. Savona   +11 more
wiley   +1 more source

Record of strep throat infections in Italy: what is needed to know about penicillin allergy? The point of view from the Italian Society of Pediatric Allergy and Immunology (SIAIP). [PDF]

Ital J Pediatr
De Filippo M, Klain A, Brambilla I, Caimmi S, Castagnoli R, Indolfi C, Dinardo G, Licari A, Martelli A, Tosca MA, Votto M, Marseglia GL, Del Giudice MM.   +12 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, EarlyView.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source